6 Best AI Drug Discovery Platforms for Biotech Teams

Key Takeaways

• The distinction that matters to an in-house team is what arrives at the end of a run. A ranked hypothesis list, a designed sequence and experimentally validated data are three different deliverables, and each leaves a different amount of work on your bench.
• Converge Bio is the strongest option for teams that want designed candidates rather than model access, with ConvergeAB combining generative, predictive and physics-based components into one antibody design system.
• Access models differ more than capabilities. Some platforms are licensed software, some are service engagements, and some are only available as a co-development partnership in which the provider shares in the asset.
• Whether your proprietary sequences and assay results train a shared model is worth settling before a pilot, not after.

A biotech team shortlisting AI drug discovery platforms is usually comparing products that are not the same kind. One vendor sells access to a model. Another runs a design campaign on your target and returns candidates. A third will only work on a shared-risk basis, taking a position in whatever comes out. All three describe themselves with the same vocabulary, and the difference only becomes concrete when the first deliverable arrives and somebody has to decide what to do with it.

For a team of twenty or fifty people, that difference is the whole decision. A ranked list of designs is useful if you have the expression and assay capacity to test them and the computational staff to interpret the results. If you do not, the same list is a cost with no obvious next step. The platforms below are separated on that basis: what they hand over, who does the experimental work, and what a team needs in place before the engagement produces anything it can act on.

At a Glance

What the Platform Hands Back

Three deliverables rest on the same promise of accelerated discovery, but they divide the work differently.

• A ranked hypothesis list. Targets, pathways or compounds ordered by predicted relevance. Cheapest to produce, and it transfers the entire burden of validation to your team.
• A designed sequence or molecule. Specific candidates generated against your criteria, usually filtered computationally before release. Your team expresses and tests them, so expression and assay capacity is the gating factor.
• Validated experimental data. Candidates the provider has already made and measured in its own laboratory. Slowest and most expensive per cycle, and the only one that arrives with evidence attached.

Match the deliverable to the capacity you have, not to the stage you wish you were at.

6 Best AI Drug Discovery Platforms for Biotech Teams

1. Converge Bio

Converge Bio is the best AI drug discovery platform for biotech teams that need designed candidates, not just access to a model. ConvergeAB, its antibody design system, combines generative models, predictive filtering, and physics-based components rather than presenting a single architecture, and the company builds these as systems around a customer’s target instead of shipping a tool for the team to operate. Predictive filtering removes low-quality candidates before downstream evaluation, which is the step that determines how much of a team’s expression and assay capacity is spent on designs that were never going to work.

The models are trained on biological sequence data, DNA, RNA, and proteins, and language models are used for auxiliary work such as literature navigation rather than for design itself. That division is worth noting, because it is the opposite of how most AI discovery tools are marketed. The company reports more than 40 completed programs with over a dozen pharma and biotech customers across North America, Europe and Israel, and antibody candidates reaching single-nanomolar binding affinity. It raised a $25 million Series A in January 2026 led by Bessemer Venture Partners, following a $5.5 million seed in 2024.

Key capabilities:

• Generative antibody design with predictive filtering applied before candidates are released
• Generative, predictive and physics-based components combined in one system
• Foundation models trained on DNA, RNA and protein sequence data
• Design programs  run against a customer’s own target and criteria
• Over 40 completed programs  with pharma and biotech customers

2. NVIDIA BioNeMo

BioNeMo is infrastructure rather than a discovery service, and it is the most directly accessible option here. The framework is open source under Apache 2.0 on GitHub, inference microservices expose the models as APIs that run on-premises or in any cloud, and reference workflows cover virtual screening and protein binder design. Models available through it include ESM-2, Evo2, AlphaFold2, DiffDock 2.0, RFdiffusion and ProteinMPNN, so a team is assembling a stack from components rather than buying an outcome.

That is also the limitation. Nothing is delivered; there is no wet lab and no validation, and the models have to be deployed, benchmarked and maintained by people who can do that work. NVIDIA reported in late 2024 that more than 200 companies were integrating BioNeMo, and named adopters include Genentech, Amgen, Ginkgo Bioworks and Argonne National Laboratory. Published figures from NVIDIA cite a fivefold AlphaFold2 speedup and DiffDock 2.0 running 6.2 times faster at 16 percent better accuracy. In January 2026 Eli Lilly announced a co-innovation AI laboratory with NVIDIA worth up to a billion dollars over five years. Pricing for the enterprise components is not published.

Key capabilities:

• Open-source framework under Apache 2.0, with inference containers for self-hosting
• Pre-trained models spanning protein structure, docking, sequence design and single-cell genomics
• Reference workflows for virtual screening and protein binder design
• Runs on premises, in any cloud, or as a managed service

3. CytoReason

CytoReason works on disease biology rather than molecule design, building computational disease models that return ranked target and patient-subgroup hypotheses with the supporting evidence attached. Each model is built to address a set of standard biological questions, with scoring drawn from a defined feature set per disease, and the output is explainable rather than a bare ranking. It is the clearest published answer in this group to the question of how a team engages: a self-service platform where the team generates and explores evidence itself, a scientific services route where CytoReason works alongside the team, or a delivered report.

It is also the only platform here that publishes how customer data is handled, stating that an organization can add proprietary data to create a model available only to it, with cross-dataset learning using summary statistics. There is no wet lab, so nothing arrives experimentally validated. The company was founded in 2016 in Tel Aviv, raised $80 million in July 2024 with participation from Pfizer and NVIDIA, and has passed $130 million in total funding. Its Pfizer alliance was extended for at least five years at up to $110 million, spanning more than 20 disease areas.

Key capabilities:

• Computational disease models returning ranked target and subgroup hypotheses
• Three published delivery modes, including a self-service tier
• Proprietary customer data can build a model private to that organization
• An agent layer that runs inside the customer’s environment

4. Simulations Plus

Simulations Plus is a listed company that has been selling discovery and development software since 1996, which makes it the most financially transparent option on this list. Its products cover simulation and prediction rather than a single AI claim: GastroPlus for physiologically based pharmacokinetics, ADMET Predictor for property prediction, and an AI-driven drug design module inside it that generates and scores novel compounds. That module runs multi-objective optimization across a Pareto front and can generate and evaluate large compound sets overnight on an ordinary laptop, with user control over which parts of a molecule may change and constraints on synthetic feasibility.

The validation record is unusually concrete for this category. The generative functionality was developed and validated with GlaxoSmithKline and published open access in 2020. The company reports a subsequent large-pharma collaboration in which nearly 30 percent of the designed molecules met a sub-50-nanomolar potency target. The US FDA has renewed and expanded its GastroPlus license. There is no wet lab, so predictions are predictions. The company guided to revenue of $79 million to $82 million for its 2026 financial year, with software a little under two-thirds of the mix.

Key capabilities:

• Generative compound design with multi-objective optimization and synthetic feasibility constraints
• ADMET property prediction and physiologically based pharmacokinetic modeling
• Co-validated with GlaxoSmithKline and published open access
• Licensed software with an optional collaborative service tier

5. Optibrium

Optibrium is the only vendor in this group that publishes what its software costs, which matters when a team has to put a number in a budget before it can evaluate anything. StarDrop, its molecular design and optimization environment, is listed from $10,000 a year for a single user, $25,000 for a small team and $60,000 for unlimited users, with academic and non-profit discounts, a free 30-day trial on the team’s own data, and no additional license cost for self-hosting. Cerella, its deep-learning imputation product, is quoted at six figures, depending on the organization and dataset size.

The technical premise is narrower than the platforms built around foundation models. Cerella works on the customer’s existing assay data, imputing missing values across compounds and endpoints so that sparse internal datasets become usable for prioritization, rather than generating candidates from a general model. BioPharmics adds three-dimensional ligand and structure-based design, and Semeta covers metabolism prediction. The company was founded in 2009 in Cambridge, England, and opened a US office in Massachusetts in 2022. There is no wet lab and no experimental component.

Key capabilities:

• Published license pricing with academic discounts and a free trial on your own data
• Deep-learning imputation across sparse internal assay datasets
• Molecular design, optimization and data analysis in one environment
• Self-hosted deployment at no additional license cost

6. Tempus AI

Tempus sits at the translational and clinical end rather than in discovery, and belongs on a shortlist for teams whose next decision concerns indication selection, biomarker strategy or trial design. Its Lens platform became commercially available in May 2026 and runs agents that convert a plain-language hypothesis into an analysis plan, execute it as code against the company’s clinical dataset, and return results with the underlying code available for inspection. The dataset behind it holds more than 8.5 million queryable de-identified patient records.

The scope boundary is worth being precise about. Tempus operates a clinical diagnostics laboratory, not a discovery laboratory, so nothing here validates a molecule or a sequence. Cohort requests are subject to internal review and approval, which makes it a licensed platform with a gate rather than open self-service. The company listed on Nasdaq in June 2024, employs roughly 3,800 people, and reported data and applications revenue of $87 million in the first quarter of 2026, up 40.5 percent year on year. It states that Lens is used by 19 of the 20 largest biopharma companies. Whether customer data is used to train shared models is not published.

Key capabilities:

• Agents that turn a stated hypothesis into an executed analysis plan
• More than 8.5 million queryable de-identified patient records
• Validated agents for biomarker work and trial design support
• Generated code available for inspection and export

How to Compare AI Drug Discovery Platforms for a Biotech Team

Four access models sit behind the platforms above, and they differ on the three things a team actually has to plan around: who operates the technology, what the team owns at the end, and how long before anything usable appears. Two points apply across all of them. None of these platforms runs a discovery wet laboratory, so experimental validation stays with your team or a contract research organization, whatever you choose. And almost none of them publish whether customer data contributes to shared models, which is a question to put in writing rather than infer.

Frequently Asked Questions

How much computational staff does a small biotech need before one of these is worth buying?

It depends entirely on the access model. Self-hosted frameworks require people who can deploy and benchmark models, typically at least one machine learning engineer alongside the scientists. Licensed platforms and design programs are built for bench scientists, so the requirement shifts from engineering capacity to assay capacity.

How much of our own data do we need to start?

For platforms that generate from general models, none: the design runs against a target and a set of criteria. For imputation and prediction tools that work on internal assay data, the existing dataset is the input, and sparse data is the normal case those products are built for rather than a disqualification.

Who owns intellectual property on an AI-designed molecule?

The contract decides, and the answer varies more than anything else in this category. Licensed software leaves the output yours. Design programs usually assign candidates to customers. Co-development partnerships explicitly do not, since the provider’s return depends on holding a share of the asset.

Can these platforms replace a medicinal chemistry or protein engineering team?

No. They change what that team spends its time on, moving effort from generating options to selecting and testing them. Every platform here produces output that requires experienced judgment to triage, and none of them runs the experiments that confirm whether the judgment was right.

How long before an engagement produces something worth acting on?

A computational cycle is usually weeks rather than months, but the gating step is downstream. Candidates still have to be expressed, synthesized, or assayed, and that queue is set by your own capacity or your contract research organization’s. Plan the validation slot before the design work starts, not after.

If you’d like to learn more, check out more articles on our blog.

Read Also

• 
  6 Best AI Drug Discovery Platforms for Biotech Teams
  Key Takeaways A biotech team shortlisting AI drug discovery platforms is usually comparing products that are not the same kind. One vendor sells access to a model. Another runs a design campaign on your target and returns candidates. A third will only work on a shared-risk basis, taking a position in whatever comes out. All… Read more: 6 Best AI Drug Discovery Platforms for Biotech Teams
• 
  Patient Engagement and Pharmaceutical Support Services: Building a Better Patient Journey
  Patients rarely experience healthcare as a simple, linear process. They may need to understand a diagnosis, determine whether they qualify for a clinical trial, gather medical records, navigate insurance requirements, arrange transportation, learn how to use a medication, and stay engaged with treatment for months or years. Serva Health is one example of a specialist… Read more: Patient Engagement and Pharmaceutical Support Services: Building a Better Patient Journey
• 
  Why Biotech Is Entering Its Most Exciting Decade
  Biotech has always been an industry built on possibility. Every year brings discoveries, new technologies, and fresh optimism about what medicine might achieve next. What’s different today is that several of those advances are beginning to happen at once. Artificial intelligence is helping researchers analyse enormous amounts of data. Cell therapies are opening new ways… Read more: Why Biotech Is Entering Its Most Exciting Decade
• 
  The Evolution of Patient Engagement: How Pharmaceutical Support Services Are Transforming Care
  The journey from receiving a complex diagnosis to successfully managing a chronic condition is rarely a straight line. For many patients, being prescribed a specialty medication or a breakthrough biologic is only the first step in a daunting process filled with administrative hurdles, financial anxiety, and clinical uncertainty. Pharmaceutical companies are increasingly realizing that simply… Read more: The Evolution of Patient Engagement: How Pharmaceutical Support Services Are Transforming Care
• 
  How to Navigate Executive Recruitment in the Pharmaceutical Sector
  Successful leadership hiring in life sciences requires a clear and structured approach. Companies need leaders who can support growth, innovation, and operational strength. Competition for top talent is high and decisions need to be precise. The process also demands a strong understanding of both science and business needs. Many organizations struggle with finding the right… Read more: How to Navigate Executive Recruitment in the Pharmaceutical Sector
• 
  Compounding Pharmacy: Personalized Medication Solutions
  A compounding pharmacy plays a vital role in modern healthcare by providing customized medications tailored to the specific needs of individual patients. Unlike mass-produced drugs manufactured by pharmaceutical companies, compounded medications are prepared by licensed pharmacists who carefully combine, adjust, or modify ingredients to create a formulation that best suits a patient’s unique medical requirements.… Read more: Compounding Pharmacy: Personalized Medication Solutions
• 
  The Function of a CRO for Clinical Trials: Structure, Responsibilities, and Operational Impact
  Clinical trials rely on organized systems that ensure scientific validity, participant protection, and regulatory compliance. As protocols become more intricate and studies expand across multiple regions, many sponsors collaborate with specialized partners to manage key operational and methodological tasks. A CRO for clinical trials provides this structured support, coordinating the activities required to move a study from… Read more: The Function of a CRO for Clinical Trials: Structure, Responsibilities, and Operational Impact